Sleep Apnea New Noninvasive Technology Launches Reports Somne

Sleep Apnea New Noninvasie Technology

Sleep Apnea globally statistics show nearly one billion adults aged 30 to 69 years are estimated to have obstructive sleep apnea (OSA).

Somne, a digital health company focused on solving sleep apnea comfortably, announced it is developing a revolutionary non-invasive alternative to CPAP.

“Somne is launching with a desire to have equal focus on patient’s comfort, adherence and efficacy. We’re utilizing variable negative pressure technology to develop this first of its kind medical device which reduces the discomfort that has plagued mass adoption of other sub-optimal products,” said Volha Hrechka, CEO of Somne. “Somne’s novel Class II medical device will be an alternative to CPAP machines and other treatments, with a more comfortable fit.”

“There are millions of people prescribed CPAP for treatment who are simply not using it. Left untreated, OSA can contribute to other serious health complications such as heart problems, high blood pressure, Type 2 diabetes, and cognitive decline,” said Dr. Jerry Kram, a sleep expert, physician, and medical advisor at Somne.  “Somne’s device could be a game-changing, innovative approach for OSA management for sleep apnea patients worldwide.  A comfortable fit from a non-intrusive device will make it easier for patients to embrace treatment.”

Somne’s device for sleep apnea treatment is worn around the neck and uses patented Variable Negative Pressure (vNEP) technology to provide therapy to patients while they sleep. The collar prototype provides gentle suction to prevent the weight of the person’s soft tissue from resting on their airway as they sleep; this keeps the patient’s airway open, assisting them to breathe normally and sleep comfortably.

Recent findings from an IRB-approved human trial of Somne’s prototype device show high efficacy and patient comfort.

Somne continues to work on product development while starting the FDA IDE Application. The company intends to bring its product to market as soon as 2024. To learn more about Somne’s sleep apnea device, visit Somne.co

Consider reading this too.

SourceSomne

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.